Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of Everolimus-Eluting bioabsorbable Polymer-Coated stent in patients with long coronary lesions: The EVOLVE 48 study.
Karmpaliotis D, Stoler R, Walsh S, El-Jack S, Potluri S, Moses J, Oldroyd K, Banning A, Webster M, Zaman A, Wu W, Ahmed M, Underwood P, Allocco D. Karmpaliotis D, et al. Among authors: moses j. Catheter Cardiovasc Interv. 2022 Feb;99(2):373-380. doi: 10.1002/ccd.29798. Epub 2021 May 29. Catheter Cardiovasc Interv. 2022. PMID: 34051049 Free PMC article.
Clinical and angiographic outcome in the laser angioplasty for restenotic stents (LARS) multicenter registry.
Giri S, Ito S, Lansky AJ, Mehran R, Margolis J, Gilmore P, Garratt KN, Cummins F, Moses J, Rentrop P, Oesterle S, Power J, Kent KM, Satler LF, Pichard AD, Wu H, Greenberg A, Bucher TA, Kerker W, Abizaid AS, Saucedo J, Leon MB, Popma JJ. Giri S, et al. Among authors: moses j. Catheter Cardiovasc Interv. 2001 Jan;52(1):24-34. doi: 10.1002/1522-726x(200101)52:1<24::aid-ccd1007>3.0.co;2-y. Catheter Cardiovasc Interv. 2001. PMID: 11146517
SMART: The microstent's ability to limit restenosis trial.
Heuser R, Lopez A, Kuntz R, Reduto L, Badger R, Coleman P, Whitlow P, Iannone LA, Safian R, Yeung A, Moses J; SMART Trial Investigators. Heuser R, et al. Among authors: moses j. Catheter Cardiovasc Interv. 2001 Mar;52(3):269-77; discussion 278. doi: 10.1002/ccd.1063. Catheter Cardiovasc Interv. 2001. PMID: 11246234 Clinical Trial.
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
Lansky AJ, Tsuchiya Y, Brener M, Mehran R, Cristea E, Pietras C, Grines CL, Cox DA, Garcia E, Tcheng JE, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Leon MB, Moses J, Stone GW. Lansky AJ, et al. Among authors: moses j. Catheter Cardiovasc Interv. 2008 Dec 1;72(7):917-24. doi: 10.1002/ccd.21714. Catheter Cardiovasc Interv. 2008. PMID: 19016469
Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DE; ENDEAVOR IV Investigators. Leon MB, et al. Among authors: moses j. JACC Cardiovasc Interv. 2010 Oct;3(10):1043-50. doi: 10.1016/j.jcin.2010.07.008. JACC Cardiovasc Interv. 2010. PMID: 20965463 Free article. Clinical Trial.
A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.
Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD; PLATINUM Trial Investigators. Stone GW, et al. J Am Coll Cardiol. 2011 Apr 19;57(16):1700-8. doi: 10.1016/j.jacc.2011.02.016. Epub 2011 Apr 4. J Am Coll Cardiol. 2011. PMID: 21470815 Free article. Clinical Trial.
1,275 results